Literature DB >> 18719384

Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.

Dmitri Lodygin1, Valery Tarasov, Alexey Epanchintsev, Carola Berking, Tatjana Knyazeva, Henrike Körner, Piotr Knyazev, Joachim Diebold, Heiko Hermeking.   

Abstract

Recently, we and others identified the microRNA miR-34a as a target of the tumor suppressor gene product p53. Ectopic miR-34a induces a G(1) cell cycle arrest, senescence and apoptosis. Here we report that miR-34a expression is silenced in several types of cancer due to aberrant CpG methylation of its promoter. 19 out of 24 (79.1%) primary prostate carcinomas displayed CpG methylation of the miR-34a promoter and concomitant loss of miR-34a expression. CpG methylation of the miR-34a promoter was also detected in breast (6/24; 25%), lung (7/24; 29.1%), colon (3/23; 13%), kidney (3/14; 21.4%), bladder (2/6; 33.3%) and pancreatic (3/19; 15.7%) carcinoma cell lines, as well as in melanoma cell lines (19/44; 43.2%) and primary melanoma (20/32 samples; 62.5%). Silencing of miR-34a was dominant over its transactivation by p53 after DNA damage. Re-expression of miR-34a in prostate and pancreas carcinoma cell lines induced senescence and cell cycle arrest at least in part by targeting CDK6. These results show that miR-34a represents a tumor suppressor gene which is inactivated by CpG methylation and subsequent transcriptional silencing in a broad range of tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18719384     DOI: 10.4161/cc.7.16.6533

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  336 in total

Review 1.  Micro-RNAs and breast cancer.

Authors:  John Le Quesne; Carlos Caldas
Journal:  Mol Oncol       Date:  2010-04-28       Impact factor: 6.603

2.  p53 and microRNA-34 are suppressors of canonical Wnt signaling.

Authors:  Nam Hee Kim; Hyun Sil Kim; Nam-Gyun Kim; Inhan Lee; Hyung-Seok Choi; Xiao-Yan Li; Shi Eun Kang; So Young Cha; Joo Kyung Ryu; Jung Min Na; Changbum Park; Kunhong Kim; Sanghyuk Lee; Barry M Gumbiner; Jong In Yook; Stephen J Weiss
Journal:  Sci Signal       Date:  2011-11-01       Impact factor: 8.192

Review 3.  Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective.

Authors:  Asfar S Azmi; Frances W J Beck; Bin Bao; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Epigenomics       Date:  2011-12       Impact factor: 4.778

Review 4.  MicroRNA in ischemic stroke etiology and pathology.

Authors:  Cameron Rink; Savita Khanna
Journal:  Physiol Genomics       Date:  2010-09-14       Impact factor: 3.107

Review 5.  Biological functions of microRNAs: a review.

Authors:  Yong Huang; Xing Jia Shen; Quan Zou; Sheng Peng Wang; Shun Ming Tang; Guo Zheng Zhang
Journal:  J Physiol Biochem       Date:  2010-10-28       Impact factor: 4.158

6.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

7.  The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.

Authors:  J Boysen; S Sinha; T Price-Troska; S L Warner; D J Bearss; D Viswanatha; T D Shanafelt; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2013-10-18       Impact factor: 11.528

Review 8.  miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.

Authors:  Paige E Bennett; Lynne Bemis; David A Norris; Yiqun G Shellman
Journal:  Physiol Genomics       Date:  2013-09-17       Impact factor: 3.107

9.  miRNA regulation of Sirtuin-1 expression in human astrocytoma.

Authors:  Sara Giovanna Romeo; Alfredo Conti; Francesca Polito; Chiara Tomasello; Valeria Barresi; Domenico La La Torre; Maria Cucinotta; Flavio Filippo Angileri; Marcello Bartolotta; Rosa Maria Di Giorgio; M'Hammed Aguennouz
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

Review 10.  MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications.

Authors:  Satyanarayana Rachagani; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2009-12-09       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.